The Du decision was a pyrrhic victory for the generics. Currently they are executing their usual strategy for a developed market with the net result that multiple companies are literally fighting over the pharma equivalent of table scraps. Yes Amarin is holding its US 60% market share but in a market that is totally stagnant with near zero growth. I historically thought that the Reduce-it data and Evaporate data was so compelling that my colleagues would do the right thing for their patients and write the scripts regardless of the usual big pharma incentives and silly TV ads. I was wrong, and I severely underestimated charlatans like Nissen, Krumholz , and Herper who waged a successful disinformation campaign to destroy Vascepa. Amarin can be 100% faulted for doing nothing to counter them.
Amarin needs a strategic reboot that may include making a deal with one of the devils, namely Teva. Teva has the firepower to bury other generics and combined with Amarin they should be able to squeeze them on price for GV so that they are forced to leave the market. A well structured deal would preserve and potentially increase the US market, leaving ROW for further growth.
Unlike previous management, Sarissa has the ability to grasp Amarin's situation and negotiate a settlement that will will slowly increase SP. When that happens, they can have a realistic discussion about acquisition. Denner historically is very meticulous, anyone expecting fireworks now will be disappointed, but a 1-2 year horizon is a necessity given expiration of international protection.
Sarissa is not in the business of losing millions of dollars. The stock is now a binary that fully depends on them.
